STAT

Opinion: Rapid expansion of telehealth comes with new challenges

Although new delivery methods will help telehealth expand, they are sometimes handcuffed by varied and conflicting state and federal rules.

It’s a boom time for telehealth. State and federal policies governing this new way to deliver medical care have helped expand access to it, while increasingly favorable regulatory changes are remaking the landscape for digital health companies hoping to revolutionize the field of medicine.

Yet this greater opportunity is accompanied by greater regulatory risk, especially with the significant state-to-state variation in laws governing telehealth and the nuanced interplay between state regulations and federal policies.

Policies around delivery, credentialing of providers, and informed consent offer insights into the complex and evolving telehealth landscape.

Challenges paying for telehealth

Telehealth has evolved dramatically from the first modality used for it — the telephone. The proliferation of new delivery methods enables providers to better tailor their care to patients’ unique needs and to increase patient autonomy and control. Unfortunately, state and federal policies about reimbursing clinicians for providing care via telehealth continue to vary widely, which is inhibiting its full potential.

Let’s start with

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks